This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Hypopharynx
CD2_BENIGN_HYPOPHARYNX_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D10
- Name in latin
- Neoplasma benignum hypopharyngis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Hypopharynx
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Hypopharynx
- Benign neoplasm of mouth and pharynx
- Benign neoplasm of mouth and pharynx
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | 61 | 98 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 58.38 | 49.61 | 63.83 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 140
- Matched controls
- 1400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.7
ICD-10 Finland
Benign neoplasm: Hypopharynx
+∞
155.9
119
*
UJC01
NOMESCO Finland
Scopy of lower throat
233.2
48.2
47
*
130
Kela drug reimbursment
Malignant tumour
+∞
36.0
33
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
29.2
27
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
120.9
27.8
29
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
86.6
25.9
28
*
C13.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of hypopharynx
+∞
17.0
16
*
2108A
ICD-9 Finland
Benign neoplasm of lip, oral cavity and pharynx, Hypopharynx
+∞
17.0
16
*
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
96.1
15.9
17
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
15.9
15
*
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
40.9
14.8
18
5
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
166.7
14.8
15
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
9.0
13.9
30
41
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
13.8
38
75
UDQ22
NOMESCO Finland
Microlaryngoscopy
44.7
13.5
16
*
H02AB02
ATC
dexamethasone; systemic
55.5
13.1
15
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
7.5
12.8
31
51
8070/3-C13.9
ICD-O-3
Squamous cell carcinoma, NOS, of hypopharynx, NOS
+∞
11.6
11
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
11.6
11
*
GBB00
NOMESCO Finland
Tracheostomy
38.5
11.5
14
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.8
11.2
60
232
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
118.5
10.6
11
*
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
+∞
10.5
10
*
R07.0
ICD-10 Finland
Pain in throat
9.3
10.3
21
26
N02AA05
ATC
oxycodone; systemic
5.1
10.1
33
79
Z51.5
ICD-10 Finland
Palliative care
23.7
9.5
13
6
C12
ICD-10 Finland
Malignant neoplasm of piriform sinus
+∞
9.5
9
*
ENA10
NOMESCO Finland
Biopsy of pharynx
+∞
9.5
9
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.4
9.1
52
207
R4190
NOMESCO Finland
Nutritional therapy
12.8
8.8
15
13
A04AA02
ATC
granisetron; systemic, transdermal
95.6
8.5
9
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
95.6
8.5
9
*
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
+∞
8.4
8
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.9
8.2
20
33
ZXC10
NOMESCO Finland
Use of laser
10.3
8.0
15
16
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
16.2
7.9
12
8
A04AA01
ATC
ondansetron; systemic, rectal
12.9
7.8
13
11
WX402
NOMESCO Finland
General anaesthesia
3.8
7.7
34
108
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
84.4
7.5
8
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.3
7
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
7.3
7
*
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
+∞
7.3
7
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
7.3
7
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
7.3
7
*
UDQ02
NOMESCO Finland
Direct laryngoscopy
31.8
7.2
9
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
5.9
7.1
19
36
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
4.6
7.0
24
60
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
42.2
6.8
8
*
K04.5
ICD-10 Finland
Chronic apical periodontitis
2.8
6.8
51
236
UJC02
NOMESCO Finland
Rigid oesophagoscopy
23.9
6.8
9
*
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
6.8
6.7
16
26
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
10.8
6.7
12
12
A02BC05
ATC
esomeprazole; systemic
2.6
6.7
70
393
R13
ICD-10 Finland
Dysphagia
4.9
6.6
21
49
C61
ICD-10 Finland
Malignant neoplasm of prostate
73.0
6.5
7
*
DQA10
NOMESCO Finland
Biopsy of larynx
73.0
6.5
7
*
JN4BD
NOMESCO Finland
Extensive body CT
6.3
6.4
16
28
XX3DW
NOMESCO Finland
Time consuming IT work
5.4
6.3
18
37
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
6.3
6
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
6.3
6
*
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
+∞
6.3
6
*
R04.2
ICD-10 Finland
Haemoptysis
9.3
6.2
12
14
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.0
6.2
38
154
ZXA00
NOMESCO Finland
Right side
2.7
6.1
49
233
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
103
571
3.28
11.73
10.8
5.3
1.2
1.2
mmol/l
1.12
94
497
84
416
3.16
11.60
4.4
2.8
—
—
—
0
0
53
200
3.48
11.52
2.8
2.4
1.1
1.0
e6/l
0.09
29
116
113
668
3.39
11.42
13.9
6.0
4.2
4.1
e9/l
0.18
105
586
70
320
3.12
10.99
3.8
2.6
0.4
0.4
e6/l
0.02
58
239
49
182
3.45
10.85
3.0
2.6
2.1
2.1
e6/l
0.02
25
98
74
364
2.93
10.00
5.0
1.9
2.3
2.4
mmol/l
0.60
65
309
90
505
2.80
9.29
7.4
3.1
33.5
36.1
g/l
3.77
81
474
12
16
8.03
8.53
1.4
1.3
—
—
—
0
0
31
102
3.53
8.12
4.4
2.9
257.9
238.8
u/l
0.23
31
95
86
513
2.47
7.28
4.7
3.6
—
—
—
0
0
53
256
2.61
6.99
2.9
1.9
—
—
—
0
0
41
174
2.83
6.96
2.2
1.7
—
—
—
0
0
21
60
3.88
6.70
2.0
1.6
—
—
—
0
0
128
949
2.79
6.38
12.4
5.1
86.1
74.7
u/l
1.30
123
874
30
114
3.01
6.16
2.1
1.7
—
—
—
0
0
29
113
2.92
5.69
2.0
1.6
—
—
—
0
0
12
25
5.11
5.59
1.8
2.8
219.6
191.4
%
0.61
12
25
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
34
4.42
5.48
2.3
2.3
0.3
0.4
u/ml
—
9
20
12
27
4.73
5.13
1.6
3.0
5.0
4.4
g/l
0.39
12
27
50
268
2.26
5.05
1.5
1.8
1.2
1.0
mg/l
0.45
45
210
43
220
2.31
4.82
3.2
1.9
2.5
2.4
mmol/l
1.02
38
183
29
127
2.57
4.53
4.2
2.5
26.6
25.3
%
0.12
29
112
49
275
2.13
4.34
1.9
1.9
2.8
3.0
mg/l
0.23
41
230
78
523
1.96
4.21
2.0
1.9
86.7
93.1
pmol/l
0.52
41
285
120
937
2.14
4.17
5.3
3.7
14.7
14.8
pmol/l
0.17
112
848
19
71
2.90
3.99
1.6
1.3
—
—
—
0
0
9
15
6.29
3.87
1.4
1.1
—
—
—
0
0
56
345
1.96
3.78
3.2
2.3
7605.4
7621.8
umol/l
0.00
49
299
23
99
2.55
3.71
3.0
1.8
63.0
62.7
ml/min/173m2
—
9
42
32
163
2.21
3.56
4.2
2.2
13.7
14.3
umol/l
0.16
32
148
146
1266
2.87
3.52
28.0
11.0
29.2
20.4
mg/l
2.64
129
974
136
1162
2.18
3.06
6.2
4.5
2.0
2.0
mu/l
0.08
128
1058
9
22
4.27
2.93
1.8
1.3
—
—
—
0
0
7
13
5.58
2.90
1.3
1.4
—
—
—
0
0
26
133
2.14
2.86
13.3
7.2
2.0
1.3
mmol/l
0.47
20
105
6
10
6.18
2.72
1.2
1.1
—
—
—
0
0
14
57
2.60
2.53
1.5
1.4
—
—
—
0
0
79
599
1.63
2.40
6.5
4.7
0.0
0.0
estimate
0.00
16
104
42
269
1.76
2.40
3.8
3.8
57.5
165.2
ng/l
0.97
35
212
80
609
1.63
2.39
4.7
3.4
0.0
0.0
estimate
0.00
14
99
31
181
1.89
2.37
1.5
1.5
—
—
—
0
0
92
730
1.62
2.29
2.7
2.7
—
—
—
0
0
138
1221
1.99
2.28
25.0
10.4
80.2
78.9
ml/min/173m2
0.27
122
994
11
42
2.74
2.23
1.2
1.1
—
—
—
0
0
78
600
1.59
2.17
4.5
3.4
0.0
0.0
estimate
0.00
16
105
6
14
4.41
2.17
1.3
1.2
—
—
—
0
0
53
381
1.59
1.92
5.7
1.9
46.0
59.8
u/l
3.36
48
357
111
943
1.59
1.90
5.4
3.8
14.3
10.3
mm/h
1.60
105
860
21
116
1.93
1.89
6.9
3.2
—
—
—
0
0
64
484
1.54
1.85
3.6
2.5
183.0
127.7
ug/l
1.18
59
443
5
12
4.26
1.83
1.2
1.2
—
—
—
0
0
9
35
2.66
1.83
1.3
1.2
—
—
—
0
0
5
13
3.93
1.73
1.2
1.0
—
—
—
0
0
102
865
1.50
1.64
4.0
3.0
75.1
46.4
u/l
1.55
94
817
128
1142
1.62
1.61
29.1
12.2
38.0
40.8
%
2.30
100
817
34
230
1.61
1.56
1.7
1.7
1014.5
1261.0
nmol/l
0.79
22
182
5
15
3.41
1.53
1.4
1.1
—
—
—
0
0
6
21
2.93
1.52
1.8
1.2
—
—
—
0
0
5
16
3.19
1.45
1.8
1.1
—
—
—
0
0
5
16
3.19
1.45
1.8
1.1
—
—
—
0
0
6
22
2.79
1.45
1.0
1.1
—
—
—
0
0
7
29
2.48
1.41
4.6
3.2
24.6
25.2
mmol/l
—
7
24
6
23
2.67
1.38
1.8
1.2
—
—
—
0
0
5
17
3.00
1.37
1.2
1.2
—
—
—
0
0
5
18
2.83
1.29
1.0
1.2
—
—
—
0
0
8
35
2.35
1.29
1.9
3.7
—
—
—
0
0
12
66
1.88
1.12
3.9
2.2
0.8
0.6
%
0.86
12
66
7
31
2.31
1.12
1.1
1.2
—
—
—
0
0
146
1376
1.75
1.11
31.1
13.3
84.4
80.5
umol/l
0.39
146
1376
12
70
1.77
0.95
3.9
2.1
2.4
1.3
%
0.84
12
70
43
338
1.37
0.95
2.5
2.6
0.8
0.8
ug/l
0.05
32
219
61
509
1.32
0.91
4.3
3.6
32.5
40.4
ng/l
0.30
47
357
6
115
0.50
0.86
1.8
1.7
—
—
—
0
0
49
405
1.30
0.77
2.5
3.1
2261.2
1079.2
ng/l
0.70
42
332
9
53
1.74
0.77
2.6
1.7
—
—
—
0
0
39
312
1.33
0.77
5.7
3.5
0.0
0.0
estimate
0.00
14
100
5
24
2.12
0.75
1.4
1.6
—
—
—
0
0
133
1253
1.38
0.74
8.0
6.1
43.4
40.2
mmol/mol
1.91
126
1171
5
26
1.95
0.71
1.0
1.5
—
—
—
0
0
5
26
1.95
0.71
2.4
1.3
—
—
—
0
0
5
28
1.81
0.66
2.0
2.1
—
—
—
0
0
5
29
1.75
0.64
1.6
1.3
—
—
—
0
0
27
211
1.34
0.62
1.3
1.2
33.1
40.5
iu/ml
—
7
65
8
50
1.63
0.62
2.0
1.5
—
—
—
0
0
14
97
1.49
0.61
1.6
1.8
—
—
—
0
0
0
23
0.00
0.59
0.0
1.2
—
7.6
—
0
13
5
35
1.44
0.39
2.0
2.1
—
—
—
0
0
5
35
1.44
0.39
1.6
1.3
—
3.0
—
0
9
138
1336
1.25
0.37
5.3
5.3
2.7
2.7
mmol/l
0.14
129
1236
41
363
1.17
0.34
1.6
1.7
1.5
1.3
mmol/l
0.92
36
312
52
478
1.13
0.26
5.7
3.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
3.2
—
14.0
—
0
11
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
94.4
—
0
5
129
1259
1.13
0.20
4.1
4.2
1.3
1.3
mmol/l
0.34
117
1163
131
1280
1.13
0.19
5.4
4.7
6.3
6.0
mmol/l
1.05
125
1168
133
1301
1.14
0.19
4.5
4.7
1.3
1.4
mmol/l
2.62
124
1207
64
610
1.08
0.15
4.3
3.8
2.0
2.0
ug/l
0.02
58
551
133
1306
1.11
0.15
4.6
4.7
4.5
4.6
mmol/l
0.61
124
1217
18
160
1.14
0.14
9.7
7.1
—
—
—
0
0
51
486
1.07
0.12
4.1
3.6
26.1
24.3
%
0.26
26
224
10
86
1.17
0.11
1.8
1.7
—
—
—
0
0
5
46
1.09
0.09
3.6
1.8
—
—
—
0
0
6
53
1.14
0.09
1.3
1.3
—
—
—
0
0
13
132
0.98
0.00
1.5
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
27
270
1.00
0.00
1.3
1.3
1.1
1.6
u/ml
—
6
79
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
0.3
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
10.1
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
0.00
1.2
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_HYPOPHARYNX_EXALLC – Benign neoplasm: Hypopharynx
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).